Inhibition of von Willebrand Factor Binding to Platelet GP Ib by a Fractionated Aurintricarboxylic Acid Prevents Restenosis After Vascular Injury in Hamster Carotid Artery
- 19 August 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 96 (4) , 1299-1304
- https://doi.org/10.1161/01.cir.96.4.1299
Abstract
Background Aurintricarboxylic acid (ATA) prevents von Willebrand factor binding to platelet glycoprotein (GP) Ib, with higher-molecular-weight ATA more effective than the lower-molecular-weight compound. We investigated the effects of high-molecular-weight ATA ( M r =7500), obtained by fractionating commercial ATA, in the injured hamster carotid artery. Methods and Results Platelet aggregation was induced in vitro with ADP (2.5 μmol/L) or botrocetin (5 μg/mL) in hamster platelet-rich plasma. IC 50 values were 348.6±22.4 and 8.2±3.2 μg/mL, respectively. The endothelium of hamster carotid artery was denuded with a modified catheter. Continuous administration of high-molecular-weight ATA (10, 30, and 100 μg·kg −1 ·h −1 ) with an infusion pump produced antithrombotic effects in a dose-dependent manner, as evaluated by prolongation of time to occlusion. Neointima formation was observed 2 weeks after catheterization, and proliferating smooth muscle cells (SMCs) were identified by the thymidine analogue 5-bromo-2-deoxy-uridine (BrdU). Continuous treatment with the compound (100 μg·kg −1 ·h −1 ) with a 2ML1 Alzet infusion pump resulted in a reduction of neointimal area by 38.0±8.8% and decreased the BrdU index on days 1 and 7 significantly. DNA synthesis in DDT1MF2 hamster SMCs was also decreased by the compound in a dose-dependent manner. In histological observation, the process of endothelial healing was improved by this treatment with the compound. Conclusions Inhibition of platelet adhesion by von Willebrand factor binding to platelet GP Ib by high-molecular-weight ATA results in the prevention of thrombus formation and the suppression of neointima lesion. In addition, high-molecular-weight ATA has an inhibitory effect on SMC proliferation. This inhibition of both platelet adhesion and SMC proliferation markedly reduced vascular stenosis.Keywords
This publication has 17 references indexed in Scilit:
- Antiplatelet Effect of FK633, a Platelet Glycoprotein Ilb/IIIa Antagonist, on Thrombus Formation and Vascular Patency after Thrombolysis in the Injured Hamster Carotid ArteryThrombosis and Haemostasis, 1997
- Selective stimulation of endothelial cell proliferation with inhibition of smooth muscle cell proliferation by fibroblast growth factor-1 plus heparin delivered from fibrin glue suspensions*Surgery, 1995
- Inhibition by aurintricarboxylic acid of von Willebrand factor binding to platelet GPIb, platelet retention, and thrombus formation in vivoAmerican Journal of Hematology, 1994
- Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor.Journal of Clinical Investigation, 1992
- Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue‐type plasminogen activatorBritish Journal of Pharmacology, 1992
- Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGFScience, 1991
- Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this modelJournal of Pharmacological Methods, 1991
- The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress.Journal of Clinical Investigation, 1991
- Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.Journal of Clinical Investigation, 1990
- Evidence that the primary binding site of von Willebrand factor that mediates platelet adhesion on subendothelium is not collagen.Journal of Clinical Investigation, 1988